These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22439785)

  • 21. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia.
    Pasinetti GM
    J Alzheimers Dis; 2002 Oct; 4(5):435-45. PubMed ID: 12446975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success.
    Sugino H; Watanabe A; Amada N; Yamamoto M; Ohgi Y; Kostic D; Sanchez R
    Clin Ther; 2015 Aug; 37(8):1632-42. PubMed ID: 26243073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
    Becker RE; Greig NH; Giacobini E
    J Alzheimers Dis; 2008 Oct; 15(2):303-25. PubMed ID: 18953116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new regulatory road-map for Alzheimer's disease drug development.
    Becker RE; Greig NH
    Curr Alzheimer Res; 2014 Mar; 11(3):215-20. PubMed ID: 24694075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.
    Batool A; Kamal MA; Rizvi SMD; Rashid S
    Curr Drug Metab; 2018; 19(8):704-713. PubMed ID: 29512457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities.
    Fu WY; Wang X; Ip NY
    ACS Chem Neurosci; 2019 Feb; 10(2):872-879. PubMed ID: 30221933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plant alkaloids as drug leads for Alzheimer's disease.
    Ng YP; Or TC; Ip NY
    Neurochem Int; 2015 Oct; 89():260-70. PubMed ID: 26220901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerating Medicines Partnership: Alzheimer's Disease (AMP-AD) Knowledge Portal Aids Alzheimer's Drug Discovery through Open Data Sharing.
    Hodes RJ; Buckholtz N
    Expert Opin Ther Targets; 2016; 20(4):389-91. PubMed ID: 26853544
    [No Abstract]   [Full Text] [Related]  

  • 30. Accelerating Alzheimer's disease drug discovery and development: what's the way forward?
    Imbimbo BP; Ippati S; Watling M; Balducci C
    Expert Opin Drug Discov; 2021 Jul; 16(7):727-735. PubMed ID: 33653187
    [No Abstract]   [Full Text] [Related]  

  • 31. Stem Cell Therapies in Alzheimer's Disease: Applications for Disease Modeling.
    Si Z; Wang X
    J Pharmacol Exp Ther; 2021 May; 377(2):207-217. PubMed ID: 33558427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.
    Coley N; Gallini A; Andrieu S
    CNS Drugs; 2015 Jul; 29(7):519-28. PubMed ID: 26188654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Was phenserine a failure or were investigators mislead by methods?
    Becker RE; Greig NH
    Curr Alzheimer Res; 2012 Dec; 9(10):1174-81. PubMed ID: 23227991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in developing novel therapeutic strategies for Alzheimer's disease.
    Cao J; Hou J; Ping J; Cai D
    Mol Neurodegener; 2018 Dec; 13(1):64. PubMed ID: 30541602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Geroneuroprotectors: Effective Geroprotectors for the Brain.
    Schubert D; Currais A; Goldberg J; Finley K; Petrascheck M; Maher P
    Trends Pharmacol Sci; 2018 Dec; 39(12):1004-1007. PubMed ID: 30446211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer's disease.
    Marei HE; Khan MUA; Hasan A
    Cell Mol Biol Lett; 2023 Nov; 28(1):98. PubMed ID: 38031028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.
    Olsson B; Schott JM; Blennow K; Zetterberg H
    Expert Rev Neurother; 2017 Aug; 17(8):767-775. PubMed ID: 28604243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.
    Wan HI; Jacobsen JS; Rutkowski JL; Feuerstein GZ
    Clin Transl Sci; 2009 Jun; 2(3):242-7. PubMed ID: 20443898
    [No Abstract]   [Full Text] [Related]  

  • 39. A map of Alzheimer's disease-signaling pathways: a hope for drug target discovery.
    Ogishima S; Mizuno S; Kikuchi M; Miyashita A; Kuwano R; Tanaka H; Nakaya J
    Clin Pharmacol Ther; 2013 May; 93(5):399-401. PubMed ID: 23511713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease.
    Li H; Wang X; Yu H; Zhu J; Jin H; Wang A; Yang Z
    Curr Neuropharmacol; 2018; 16(6):758-768. PubMed ID: 29086699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.